MD Anderson Cancer Center

Company

Also known as: MD Anderson

Related News

Compass Therapeutics Reports Mixed Biliary Tract Cancer Data, Plans FDA Meeting for Tovecimig BLA

Apr 28, 2026

Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.

New Biomarker Outperforms Existing Methods for Predicting Chemotherapy Response in TNBC

Feb 18, 2026

Researchers at The University of Texas MD Anderson Cancer Center developed a computational approach using tumor-specific total mRNA expression (TmS) that outperformed current methods for predicting chemotherapy response in triple-negative breast cancer patients.